This article has Open Peer Review reports available.
Double-blinded, randomized controlled trial comparing real versus placebo acupuncture to improve tolerance of diagnostic esophagogastroduodenoscopy without sedation: a study protocol
- P Knebel1Email author,
- K Schwan2,
- T Bruckner3,
- CM Seiler1,
- K Plaschke2,
- K Streitberger4,
- A Schaible†1 and
- C Bopp†2
© Knebel et al; licensee BioMed Central Ltd. 2011
Received: 10 August 2010
Accepted: 23 February 2011
Published: 23 February 2011
Sedation prior to performance of diagnostic esophagogastroduodenoscopy (EGDE) is widespread and increases patient comfort. But 98% of all serious adverse events during EGDEs are ascribed to sedation. The S3 guideline for sedation procedures in gastrointestinal endoscopy published in 2008 in Germany increases patient safety by standardization. These new regulations increase costs because of the need for more personnel and a prolonged discharge procedure after examinations with sedation. Many patients have difficulties to meet the discharge criteria regulated by the S3 guideline, e.g. the call for a second person to escort them home, to resign from driving and working for the rest of the day, resulting in a refusal of sedation. Therefore, we would like to examine if an acupuncture during elective, diagnostic EGDEs could increase the comfort of patients refusing systemic sedation.
A single-center, double blinded, placebo controlled superiority trial to compare the success rates of elective, diagnostic EGDEs with real and placebo acupuncture. All patients aged 18 years or older scheduled for elective, diagnostic EGDE who refuse a systemic sedation are eligible. 354 patients will be randomized. The primary endpoint is the rate of successful EGDEs with the randomized technique. Intervention: Real or placebo acupuncture before and during EGDE. Duration of study: Approximately 24 months.
Organisation/Responsibility The ACUPEND - Trial will be conducted in accordance with the protocol and in compliance with the moral, ethical, and scientific principles governing clinical research as set out in the Declaration of Helsinki (1989) and Good Clinical Practice (GCP). The Interdisciplinary Endoscopy Center (IEZ) of the University Hospital Heidelberg is responsible for design and conduct of the trial, including randomization and documentation of patients' data. Data management and statistical analysis will be performed by the independent Institute for Medical Biometry and Informatics (IMBI) and the Center of Clinical Trials (KSC) at the Department of General, Visceral and Transplantation Surgery, University of Heidelberg.
The trial is registered at Germanctr.de (DRKS00000164) on December 10th 2009. The first patient was randomized on February 2nd 2010.
More than 10 million gastrointestinal (GI) endoscopic procedures are performed every year in the United States only[1, 2]. The standard use of systemic sedation to facilitate the performance of esophagogastroduodenoscopy (EGDE) and to increase patient comfort has contributed to the widespread use and acceptance of this procedure. But the perceived benefits of improved patient comfort and satisfaction afforded by parenteral sedation must be measured against the increased risk of adverse cardiopulmonary events and higher attendant costs. Complications that arise from EGDE are usually associated with the use of systemic sedation and the dose given. More than 98% of serious adverse events in upper GI endoscopy like hypotension, aspiration and respiratory depression are ascribed to systemic sedation.
Recently, the first S3-guideline for sedation in GI endoscopy in Germany was published to improve patient safety, which demands additional trained personnel and endoscopy equipment. Therefore, it is estimated that sedation and related issues account for up to 40% of total endoscopy costs including overhead and indirect costs. In detail, an additional specialized nurse or physician is required to perform and monitor systemic sedation. Furthermore, systemic sedation impedes the rapid discharge from the hospital, resulting in absence of work of patients concerned.
If the use of acupuncture could improve tolerance and examination quality of diagnostic EGDE without sedation it should be possible to increase the willingness of patients to undergo this examination without systemic sedation. Consequently, it would be possible to reduce the rate of serious adverse events due to systemic sedation and to lower the costs for personnel and material.
Up to now, only one double-blind, controlled trial with 90 patients undergoing EGDE was performed in 1978, using real versus sham-acupuncture (1 cm away from the acupuncture point) with 10 needles and electrical stimulation and showing that upper endoscopy was much easier and better tolerated after real acupuncture. But this study misses a clearly defined primary endpoint and a detailed sample size calculation and has the disadvantage of using sham-acupuncture instead of a real placebo acupuncture technique in the control group. An adequately designed randomized double-blinded placebo controlled clinical trial with a well-defined primary endpoint and detailed sample size calculation comparing placebo acupuncture versus real acupuncture to improve success rates in EGDE has not yet been conducted.
Aim of study
The objective of this trial is to compare the rate of successful EGDE (combination of patients' satisfaction and examination quality) in patients receiving pharyngeal anaethesia as well as either real or placebo acupuncture.
Number of patients needed
The sample size calculation is based on the two-sided chi-square test for difference with respect to the primary endpoint.
Age equal or greater than 18 years
Patients scheduled for elective diagnostic EGDE without systemic sedation
Patients classified ASA V
Participation in another clinical trial which could interfere with the primary endpoint of this study
Expected lack of compliance
Impaired mental state or language problems
Patients with known allergy to lidocaine anaesthetic spray or acupuncture needle material
Necessity of systemic sedation
Subject withdrawal criteria
At their own request or at request of the legal representative
If, in the investigator's opinion (physician performing the acupuncture or physician performing the examination), continuation of the trial would be detrimental to the subject's well-being (e.g. strong pain at the insertion points, allergical reactions, other independent acute health problems).
All withdrawn patients will be reported in the final results to guarantee maximum transparency.
The ACUPEND- Trial will be conducted in accordance with the protocol and in compliance with the moral, ethical, and scientific principles governing clinical research as set out in the Declaration of Helsinki 1989 and Good Clinical Practice http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf. The protocol was approved by the Ethics Committee of the University of Heidelberg (S-273/2009). All patients scheduled for an elective diagnostic EGDE in the Interdisciplinary Center of Endoscopy (IEZ) of the Department of General, Visceral and Transplantation Surgery and the Department of Internal Medicine of the Universitiy of Heidelberg will be screened, informed about the ACUPEND trial and included by physicians of the IEZ supervising in this trial. The study procedure, risks, benefits and data management will be clarified in detail before the patients are asked to give their informed consent.
Randomization and procedures for minimizing bias
The study protocol was designed according to the Standards for reporting Interventions in Clinical Trials Acupuncture (STRICTA).
To achieve comparable groups for known and unknown risk factors, randomization will be performed as a block randomization with alternating block size. Allocation to treatment group will be performed by sealed consecutively numbered envelopes prepared by the Institute of Medical Biometry and Informatics of the University of Heidelberg (IMBI). Randomization will be carried out after the patient has signed the informed consent form and will be documented in the case report file of every patient. The allocation will be controlled by a monitor.
Minimizing treatment bias
All physicians who participate in this trial will be trained and updated every 3 month to improve comparable treatment of patients.
Special manuals will be used in the Interdisciplinary Center for Endoscopy (IEZ) to reduce errors. Acupuncture will be performed by physicians of the department of the Interdisciplinary endoscopy center (IEZ) who were trained by experienced acupuncturists with level B diploma and who performed at least 20 acupuncture procedures explained in the intervention chapter under supervision. Furthermore the PS3 device will be used to support the localisation of the correct acupuncture points by measuring loss of skin resistance.
Minimizing measurement bias
A study nurse or physician will document and monitor the procedure in the endoscopy and recovery room. Before the endoscopic procedure is performed the acupuncturist will open the allocation envelope. The physician performing the EGDE and the assistant nurse will not be informed about the allocation. Once patients are randomized they will be included into the analysis according to the principle of intention to treat.
Study Visit Schedule
Day of screening and intervention
Past medical history*
Examination of primary endpoints:
• Success of EGDE
Examination of secondary endpoints:
• Heart rate
• Blood pressure
• Oxygen saturation
• Duration of examination
• Willingness to repeat examination under same conditions
• Periinterventional complications
Safety criteria AE, SAE (2.6)
All patients will be positioned on a stretcher lying on their backs with 30 degrees reverse Trendelenburg's position. Standard monitoring with SaO2 and non-invasive blood pressure will be established. Pharyngeal anaesthesia will be performed with a topical xylocaine spray (AstraZeneca, Germany) in all patients by a nurse or physician.
According to the allocation the procedure will be continued
We based the acupuncture point selections on Traditional Chinese Medicine meridian theory to improve tolerance and examination quality of diagnostic EGDE.
Intervention-group A (placebo acupuncture)
KG 24 Chengjiang middle line (to reduce choking)
Pericard 6 Neiguan bilateral (to reduce gastroenteral motility)
Di 4 Yangxci bilateral (to reduce nausea and vomiting)
Half to one inch 32G needles (0.32 × 30 mm stainless steel needle from asia med company, Munich, Germany) will be placed and left in their position for five minutes prior and throughout the endoscopic procedure.
Intervention-group B (real acupuncture)
After the described preparation patients will receive a real acupuncture at the following acupuncture points:
KG 24 Chengjiang middle line (to reduce choking)
Pericard 6 Neiguan bilateral (to reduce gastroenteral motility) 
Di 4 Yangxci bilateral (to reduce nausea and vomiting)
Half to one inch 32G needles (0.32 × 30 mm stainless steel needle from asia med company, Munich, Germany) will be placed into these points, stimulated for 1-2 seconds to induce de qi sensation and left in this position for five minutes prior and throughout the endoscopic procedure.
To perform EGDE all patients in both groups will be turned on their left side still with a 30 degree reverse Trendelenburg's position.
Primary and secondary endpoints
The primary endpoint will be the rate of successful diagnostic EGDE.
Definition of the primary endpoint
Rate of successful elective diagnostic EGDE is defined as a composite score of patient satisfaction with the procedure as well as quality of the examination (technical adequacy) as assessed by the examiner. These were determined by the administration of standardized Likert scales.
Assessment of the primary endpoint
Immediately after the elective diagnostic EGDE, the examiner scores the technical adequacy of the examination. Each anatomic area (esophagus, stomach, duodenum up to the second stage, and proximal stomach viewed in retroflexion) that was adequately viewed receives a score of 1 versus 0 if inadequately viewed, for a maximum score (4/4) if all four main anatomic areas of the examination were well visualized. The result will be documented in the CRF with tick boxes by the physician who performed the examination.
The patients are asked to rate their satisfaction with the examination after the completion of EGDE, prior to being told the results of their procedure and prior to discharge from the recovery room, on a Likert scale from 1 = acceptable to 5 = unacceptable. The results will be documented in the CRF with tick boxes by a nurse or physician. An EGDE will be counted as success if patients' satisfaction is 1 or 2 on the Likert scale and the examination quality score is 4/4[12, 18–20].
Definitions of periinterventional complications:
Heart rate < 60 beats per minute
Blood pressure < 90 mmHg systolic
Low oxygen saturation
Oxygen saturation < 92%
Clinical diagnosis and radiological findings
Specification of safety variables
The correct placement of the needles will be checked and if necessary replaced by the physician who performed the acupuncture right before the examination. After endoscopic examination the needles will be checked again. If some of the needles are not in place after examination it will be documented in the CRF.
Every patient can be switched to systemic sedation at anytime to successfully complete the EGDE if necessary or at the patient's wish. The conversion will be documented in the CRF and the patient's satisfaction will be counted as 5/5 (unacceptable) on the Likert scale. Therefore, the need for systemic sedation is defined as unsuccessful EGDE for both intervention groups.
Past medical history
Prior and concomitant illness of the patients will be documented in the CRF.
Adverse events and serious adverse events
AEs will be reported to the principal investigator in regular intervals during the course of the study. SAEs will be documented on a special SAE form in the CRF and will be reported to the principal investigator within 24h.
Each patient's allocation to the different analysis populations (full analysis set (FAS) according to the intention-to-treat (ITT) principle, per protocol (PP) analysis set, safety analysis set) will be defined prior to the analysis. The allocation will be documented in the statistical analysis plan. During the data review, deviations from the protocol will be assessed as "minor" or "major". Major deviations from the protocol will lead to the exclusion of a patient from the PP analysis set.
The null hypothesis H is assessed by testing the intervention effect in a primary analysis using a two-sided chi-square test. In a secondary analysis a binary logistic regression model that takes into account the covariates "intervention" (placebo/acupuncture), age (< 65,≥ 65) and gender will be used. A two-sided type I error rate of α = 0.05 will be applied to the primary and secondary analysis.
Confirmatory analysis will be primarily based on the FAS which is consistent with the intention-to-treat (ITT) principle, by including all patients who were randomized into the two groups. This approach reflects the idea that the study should correspond to the conditions in clinical practice as closely as possible.
In addition to the evaluation of the FAS, a PP analysis will be performed including all randomized patients without major protocol violations.
The secondary variables will be analyzed in a descriptive manner by tabulation of the measures of the empirical distributions. According to the scale level of the variables, means, standard deviations, medians, 1st and 3rd quartiles as well as minimum and maximum or absolute and relative frequencies, respectively, will be reported. Descriptive p-values of the corresponding statistical tests comparing the treatment groups and associated 95% confidence intervals will be given.
Homogeneity of the treatment groups
The homogeneity of the treatment groups will be demonstrated descriptively using the demographic data and the baseline values. All statistical analyses will be performed using SAS® software, Version 9.1 (or higher) of the SAS System for Unix (SAS Institute Inc., Cary, NC, USA).
After approval of the protocol by the local ethics committee of the University of Heidelberg, the trial was internationally registered at Germanctr.de (DRKS00000164). All patients scheduled for elective, diagnostic EGDE in the Interdisciplinary Endoscopy Center (IEZ) who refuse sedation will be referred to and screened by members of IEZ or the Clinical Study Center Surgery (KSC). The result of the screening will be recorded in the screening-log.
Approximately 4300 patients per year undergo an EGDE including about 900 patients without systemic sedation in the Interdisciplinary Center for Endoscopy (IEZ) of the Universitiy of Heidelberg. The estimated time frame to randomize 354 patients is 20 months.
Sponsor of the ACUPEND trial is the University Hospital of Heidelberg.
The independent data management and statistical analysis will be carried out by the Institute of Medical Biometry and Informatics (IMBI) of the University of Heidelberg according to a prespecified Statistical Analysis Plan.
The principal investigator has the right to terminate the trial and to remove all trial material from the trial centre at any time in consultation with the Clinical Study Team Leader and the Biostatistician. Reasons that may require a termination of the trial include the following:
The incidence or severity of adverse events in this trial indicates a potential health hazard caused by the study treatment
It appears that patient's enrolment is unsatisfactory with respect to quality or quantity or data recording is severely inaccurate or incomplete
External evidence that renders the necessity to terminate the trial
The trial will be sponsored by the regular research budget (State of Baden-Württemberg) of the Clinical Study Center Surgery (KSC), Department of General, Visceral and Transplantation Surgery of the University of Heidelberg and the IEZ.
MWB and EM provided general support as head of the department of General, Visceral and Transplantation Surgery and Anaesthesiology.
- Morrissey JF, Reichelderfer M: Gastrointestinal endoscopy (1). N Engl J Med. 1991, 325: 1142-1149. 10.1056/NEJM199110173251606.View ArticlePubMedGoogle Scholar
- Morrissey JF, Reichelderfer M: Gastrointestinal endoscopy (2). N Engl J Med. 1991, 325: 1214-1222. 10.1056/NEJM199110243251705.View ArticlePubMedGoogle Scholar
- Thompson AM, Wright DJ, Murray W, Ritchie GL, Burton HD, Stonebridge PA: Analysis of 153 deaths after upper gastrointestinal endoscopy: room for improvement?. Surg Endosc. 2004, 18: 22-25. 10.1007/s00464-003-9256-9.View ArticlePubMedGoogle Scholar
- Quine MA, Bell GD, McCloy RF, Charlton JE, Devlin HB, Hopkins A: Prospective audit of upper gastrointestinal endoscopy in two regions of England: safety, staffing, and sedation methods. Gut. 1995, 36: 462-467. 10.1136/gut.36.3.462.View ArticlePubMedPubMed CentralGoogle Scholar
- Riphaus A, Wehrmann T, Weber B, Arnold J, Beilenhoff U, Bitter H, von Delius S, Domagk D, Ehlers AF, Faiss S: [S3-guidelines--sedation in gastrointestinal endoscopy]. Z Gastroenterol. 2008, 46: 1298-1330. 10.1055/s-2008-1027850.View ArticlePubMedGoogle Scholar
- Mokhashi MS, Hawes RH: Struggling toward easier endoscopy. Gastrointest Endosc. 1998, 48: 432-440. 10.1016/S0016-5107(98)70021-5.View ArticlePubMedGoogle Scholar
- Kaptchuk TJ: Acupuncture: theory, efficacy, and practice. Ann Intern Med. 2002, 136: 374-383.View ArticlePubMedGoogle Scholar
- Usichenko TI, Lehmann C, Ernst E: Auricular acupuncture for postoperative pain control: a systematic review of randomised clinical trials. Anaesthesia. 2008, 63: 1343-1348. 10.1111/j.1365-2044.2008.05632.x.View ArticlePubMedGoogle Scholar
- Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR: Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev. 2009, CD001218-Google Scholar
- Streitberger K, Kleinhenz J: Introducing a placebo needle into acupuncture research. Lancet. 1998, 352: 364-365. 10.1016/S0140-6736(97)10471-8.View ArticlePubMedGoogle Scholar
- Cahn AM, Carayon P, Hill C, Flamant R: Acupuncture in gastroscopy. Lancet. 1978, 1: 182-183. 10.1016/S0140-6736(78)90614-1.View ArticlePubMedGoogle Scholar
- Abraham NS, Fallone CA, Mayrand S, Huang J, Wieczorek P, Barkun AN: Sedation versus no sedation in the performance of diagnostic upper gastrointestinal endoscopy: a Canadian randomized controlled cost-outcome study. Am J Gastroenterol. 2004, 99: 1692-1699. 10.1111/j.1572-0241.2004.40157.x.View ArticlePubMedGoogle Scholar
- Deutsch E: Medical experimentation: international rules and practice. Law Rev. 1989, 19: 1-10.PubMedGoogle Scholar
- MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A, Moher D: Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 7: e1000261-10.1371/journal.pmed.1000261.Google Scholar
- Stux G, Stiller N, Berman B, Pomeranz B: Akupunktur - Lehrbuch & Atlas. 7. Auflage edn. 2007, Berlin: SpringerGoogle Scholar
- Streitberger K, Ezzo J, Schneider A: Acupuncture for nausea and vomiting: an update of clinical and experimental studies. Auton Neurosci. 2006, 129: 107-117. 10.1016/j.autneu.2006.07.015.View ArticlePubMedGoogle Scholar
- Chernyak G, Sengupta P, Lenhardt R, Liem E, Doufas AG, Sessler DI, Akca O: The timing of acupuncture stimulation does not influence anesthetic requirement. Anesth Analg. 2005, 100: 387-392. 10.1213/01.ANE.0000142114.72117.E0.View ArticlePubMedPubMed CentralGoogle Scholar
- Abraham N, Barkun A, Larocque M, Fallone C, Mayrand S, Baffis V, Cohen A, Daly D, Daoud H, Joseph L: Predicting which patients can undergo upper endoscopy comfortably without conscious sedation. Gastrointest Endosc. 2002, 56: 180-189. 10.1016/S0016-5107(02)70175-2.View ArticlePubMedGoogle Scholar
- Streiner D, Norman G: Health measurement scales. 1995, New York: Oxford University PressGoogle Scholar
- Walmsley RS, Montgomery SM: Factors affecting patient tolerance of upper gastrointestinal endoscopy. J Clin Gastroenterol. 1998, 26: 253-255. 10.1097/00004836-199806000-00006.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.